HYDROXOMIN Drug Patent Profile
✉ Email this page to a colleague
When do Hydroxomin patents expire, and when can generic versions of Hydroxomin launch?
Hydroxomin is a drug marketed by Bel Mar and is included in one NDA.
The generic ingredient in HYDROXOMIN is hydroxocobalamin. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydroxocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hydroxomin
A generic version of HYDROXOMIN was approved as hydroxocobalamin by ACTAVIS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDROXOMIN?
- What are the global sales for HYDROXOMIN?
- What is Average Wholesale Price for HYDROXOMIN?
Summary for HYDROXOMIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| DailyMed Link: | HYDROXOMIN at DailyMed |
US Patents and Regulatory Information for HYDROXOMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bel Mar | HYDROXOMIN | hydroxocobalamin | INJECTABLE;INJECTION | 084629-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for HYDROXOMIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| SERB SA | Cyanokit | hydroxocobalamin | EMEA/H/C/000806 Treatment of known or suspected cyanide poisoning.Cyanokit is to be administered together with appropriate decontamination and supportive measures. |
Authorised | no | no | no | 2007-11-23 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
